Daniel Hübschmann

Has grant

Research Group Leader

Deutsches Krebsforschungszentrum
Country flagGermany

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

MD/PhD-program

Open Date: 2014-03-01

Close Date: 2017-02-01

Grant: Close

Exchange grant Suisse Occidentale Leonardo

Open Date: 2009-01-01

Close Date: 2010-01-01

Grant: Close

Marc-Dünzl-Preis

Open Date: 2009-01-01

Close Date: 2009-01-01

Grant: Close

DAAD Student Fellowship

Open Date: 2002-01-01

Close Date: 2003-01-01

Articles (14)

Rare cancers are individually uncommon but collectively represent a substantial share of cancer burden, with limited systemic treatment options for many entities. Molecular profiling identifies targetable alterations, but actionable findings are limited and responses can vary despite a matched target. This motivates complementary approaches that directly assess tumor drug response. Here, we establish a biopsy-compatible ex vivo drug sensitivity testing platform optimized for low input and reproducibility. Patient-derived material was tested either directly or following ex vivo expansion. Functional profiling was performed within clinically relevant timelines across models from 126 patients with rare advanced solid tumors. Drug responses were consistent between model types. In most samples, we identified at least one potentially active compound, supporting feasibility at biopsy-scale. High in vitro sensitivity was associated with clinical benefit and progression-free survival. These findings support functional drug sensitivity testing as a complementary component in precision oncology for adults with rare cancers. Statement of Significance This study presents a biopsy-compatible drug sensitivity testing platform for phenotype-based therapy stratification in rare cancers. It identifies actionable ex vivo drug responses and shows associations with clinical outcome in patients treated with screened therapies. These findings support functional testing as a complementary additional layer of stratification for therapeutic prioritization.

Year:

2026

Precision cancer medicine aims to improve patient outcomes by providing individually tailored recommendations for clinical management based on the evaluation of biological disease profiles in multidisciplinary molecular tumor boards (MTBs). The quality of MTB decisions depends on the comprehensive, reliable, and reproducible interpretation of increasingly complex molecular data. We developed and implemented, as part of a multicenter precision oncology program, the Knowledge Connector (KC), a decision support system that integrates individual patients’ molecular and clinical data with world knowledge to generate and document MTB recommendations. The KC supports data curation, database integration, and discussion based on multiomics data and provides an interface for creating a cross-institutional knowledge base. Furthermore, it extracts relevant biomarker-drug associations and increases the efficacy of data interpretation in a clinically relevant manner by reducing reliance on external sources and optimizing inter-curator concordance. Our results demonstrate that the KC is a versatile tool that supports medical decision-making in MTBs, thus enabling the scalability of precision cancer medicine.

Year:

2026

Accurate risk stratification is essential to prevent over- and undertreatment in newly diagnosed prostate cancer (PCa). In a pilot study with 49 men (36 PCa patients, 13 controls), we integrated non-invasive data modalities collected in a real-world clinical setting: radiomics from multiparametric magnetic resonance imaging (T2/ADC index-lesion features), routine and extended serological parameters, multimodal liquid biopsy features (copy number variations, chromosomal instability, methylation, fragmentation in plasma/urinary cfDNA), plus clinical and lifestyle factors. Pairwise Spearman analyses revealed significant inter-modality correlations. Our holistic PCa characterization showed that imaging phenotypes reflect tumor stage and molecular aggressiveness: lower ADC metrics correlated inversely with genomic cfDNA features, while ADC/T2 lesion volumes correlated positively with molecular signals. These results indicate that routine imaging and serological data may capture systemic tumor biology. Our proof-of-concept demonstrates feasibility of combining multiple data modalities in real-world clinical workflows and supports developing integrative models for non-invasive PCa risk stratification.

Year:

2025

Background and Objective Prostate cancer (PCa) is a heterogeneous disease, impeding early detection and risk stratification. Liquid biopsies (LBx) enable minimally invasive tumor profiling, but circulating tumor-derived DNA (ctDNA) detection remains difficult, especially in early-stage PCa. This study aimed at developing a multimodal LBx approach, analyzing genomic and epigenomic cell-free DNA (cfDNA) features in plasma and urine from newly diagnosed PCa patients for early detection, tumor characterization, and risk stratification of aggressive PCa. Methods Plasma and urine samples were included from 55 localized PCa (lPCa) patients, 18 advanced PCa (aPCa) patients, and 36 cancer-free controls. Low-coverage whole-genome sequencing and methylated DNA immunoprecipitation sequencing were performed to assess fragmentation, chromosomal instability, and methylation in cfDNA. Key findings and Limitations The complementary (epi)genomic analysis of plasma and urinary cfDNA achieved a 45% ctDNA detection rate in newly diagnosed PCa. Major differences were observed between aPCa and controls, reflecting increasing signals with tumor progression. Epigenomic cfDNA features differentiated lPCa from aPCa, and ctDNA was detected in 46% of PCa patients with prostate-specific antigen <10 ng/ml, suggesting potential for risk stratification. However, sensitivity in early PCa remains a major limitation. Conclusions and Clinical Implications This study highlights the potential of multimodal LBx approaches, integrating genomic and epigenomic cfDNA features, for minimally invasive characterization of primary PCa and potential metastasis at initial diagnosis. While promising for risk stratification, sensitivity requires optimization for early detection. Incorporating LBx into clinical workflows could complement diagnostics and support clinical decision-making for personalized treatments tailored to patients’ PCa risk profiles.

Year:

2025

Desmoplastic small round cell tumor (DSRCT) is an ultra-rare sarcoma with limited treatment options. We performed whole-genome/exome, transcriptome, and DNA methylome analysis in 30 refractory DSRCT patients, complemented by (phospho)proteomic profiling in nine, within a nationwide precision oncology program. In eight patients (27%), DSRCT was diagnosed based on molecular profiling. Although all patients had “quiet” genomes, 28 (93%) received 107 molecular-based management recommendations, including assessment of clinical trial eligibility in 17 (57%). Nearly half of recommendations (45%) were based on overexpression of tyrosine kinases, as well as SSTR3/5 and CLDN6, detected in 33% and 20% of cases, respectively. Thirteen patients (46%) received recommended therapies, yielding disease control in eight (62%; partial response, n = 5; stable disease, n = 3), including three long-lasting responses (≥ 12 months) to pazopanib and trastuzumab deruxtecan, triggered by ERBB2 overexpression in the absence of constitutive ERBB2 signaling. Thus, multi-omics profiling enables individualized DSRCT treatment.

Year:

2025

Residing at the top of the hematopoietic hierarchy, long-term hematopoietic stem cells (HSCs) are capable of self-renewal and sustained blood cell regeneration. Over the past decades, single-cell and clonal analyses have revealed substantial functional and molecular heterogeneity within this compartment, challenging the notion that self-renewal is inherently tied to balanced, multi-lineage blood production. However, a cohesive model that explains the relationships among these diverse HSC states remains elusive. Here, we combined single-cell transplantations of over 1,000 highly purified murine long-term HSCs with in-depth phenotyping of their clonal progeny to achieve a detailed, time-resolved understanding of heterogeneous reconstitution outcomes. We identified reconstitution kinetics as an overall unifying metric of HSC functional potency, with the most potent HSCs displaying the greatest delay in hematopoietic reconstitution. Importantly, a progressive acceleration in reconstitution kinetics was also associated with a gradual shift in mature cell production from platelet and erythro-myeloid bias to balanced, and eventually lymphoid bias. Serial single-cell transplantations of HSCs revealed a unidirectional acceleration in reconstitution kinetics accompanied by a gradual decline in functional potency of daughter HSCs, aligning diverse phenotypes along a linear hierarchical trajectory. Mathematical modeling, together with experimental modulation of lineage-biased blood production, demonstrated that apparent lineage biases actually arise from cell-extrinsic feedback regulation and clonal competition between slow- and fast-engrafting clones to occupy the limited compartment sizes of mature lineages. Our study reconciles multiple layers of HSC heterogeneity into a unifying framework, prompting a reevaluation of the meaning of lineage biases in both normal and diseased hematopoiesis, with broad implications for other regenerating tissues during development, homeostasis, and repair.

Year:

2025

The long-term consequences of cancer and its therapy on the patients’ immune system years after cancer-free survival remain poorly understood. Here, we present an in-depth characterization of the bone marrow immune ecosystem of multiple myeloma long-term survivors, from initial diagnosis up to 17 years following a single therapy line and cancer-free survival. Using comparative single-cell analyses combined with molecular, genomic, and functional approaches, we demonstrate that multiple myeloma long-term survivors exhibit pronounced alterations in their bone marrow microenvironment associated with impaired immunity. These immunological alterations were frequently linked to an inflammatory immune circuit fueled by the long-term persistence or resurgence of residual myeloma cells. Notably, even in the complete absence of any detectable residual disease for decades, sustained changes in the immune system were observed, suggesting an irreversible ‘immunological scarring’ caused by the initial exposure to the cancer and therapy. Collectively, our study provides key insights into the molecular and cellular bone marrow ecosystem of long-term survivors of multiple myeloma, revealing both reversible and irreversible alterations in the immune compartment.

Year:

2024

Background Salivary gland cancers (SGC) are rare and heterogeneous malignant tumors. Advanced SGC lack established treatment options and show poor response to immunotherapy. Here, an integrative multi-omics analysis in a large cohort of advanced SGC revealed insights into the tumor immune microenvironment (TIM) and distinct mechanisms of immune evasion. Methods A total of 104 patients with recurrent/metastatic SGC from the DKTK MASTER program were included in this study. Whole-exome or whole-genome sequencing and RNA-sequencing was performed on fresh frozen tumor tissue. The tumor immune microenvironment was analyzed using CIBERSORT deconvolution analysis and immune gene expression scores in bulk RNA-sequencing data. Single-nuclei sequencing and immunohistochemistry analyses were performed in selected samples. Results were validated in bulk RNA-sequencing data of a previously published independent dataset. Results Bulk transcriptome analysis revealed an immune-deserted TIM in the majority of advanced SGC samples. Immune exclusion was most prominent in adenoid cystic carcinoma (ACC) subgroup 1 exhibiting a downregulation of the antigen processing machinery. Only a small subset of advanced SGC, including few adenoid cystic carcinoma, exhibited T-cell inflammation, which was correlated with tumor mutational burden in Non-ACC samples. Subtype specific expression of immune checkpoints as well as cancer testis antigens were identified with prominent expression of VTCN1 in luminal cells within ACC. Single-cell RNA-sequencing and bulk RNA-seq deconvolution analysis validated immune cell exclusion and revealed a TIM that was dominated by M2 macrophages across SGC subtypes. Among evaluable patients treated with immune checkpoint inhibitors, a high T-cell to macrophage ratio was associated with clinical benefit. Conclusions These data support biomarker-based development of immune-checkpoint inhibition and the development of novel immune-checkpoint inhibitors and cellular therapies in SGC. Trial Registration Retrospectively registered, NCT05852522

Year:

2024

Purpose: AcSé-ESMART Arm C aimed to define the recommended dose and activity of the WEE1 inhibitor adavosertib in combination with carboplatin in children and young adults with molecularly enriched recurrent/refractory malignancies. Patients and Methods: Adavosertib was administered orally, twice every day on Days 1 to 3 and carboplatin intravenously on Day 1 of a 21-day cycle, starting at 100 mg/m 2 /dose and AUC 5, respectively. Patients were enriched for molecular alterations in cell cycle and/or homologous recombination (HR). Results: Twenty patients (median age: 14.0 years; range: 3.4–23.5) were included; 18 received 69 treatment cycles. Dose-limiting toxicities were prolonged grade 4 neutropenia and grade 3/4 thrombocytopenia requiring transfusions, leading to two de-escalations to adavosertib 75 mg/m 2 /dose and carboplatin AUC 4; no recommended phase II dose was defined. Main treatment-related toxicities were hematologic and gastrointestinal. Adavosertib exposure in children was equivalent to that in adults; both doses achieved the cell kill target. Overall response rate was 11% (95% confidence interval, 0.0–25.6) with partial responses in 2 patients with neuroblastoma. One patient with medulloblastoma experienced unconfirmed partial response and 5 patients had stable disease beyond four cycles. Seven of these eight patients with clinical benefit had alterations in HR, replication stress, and/or RAS pathway genes with or without TP53 alterations, whereas TP53 pathway alterations alone (8/10) or no relevant alterations (2/10) were present in the 10 patients without benefit. Conclusions: Adavosertib–carboplatin combination exhibited significant hematologic toxicity. Activity signals and identified potential biomarkers suggest further studies with less hematotoxic DNA-damaging therapy in molecularly enriched pediatric cancers.

Year:

2024

Purpose: AcSé-ESMART Arm C aimed to define the recommended dose and activity of the WEE1 inhibitor adavosertib in combination with carboplatin in children and young adults with molecularly enriched recurrent/refractory malignancies. Patients and Methods: Adavosertib was administered orally, twice every day on Days 1 to 3 and carboplatin intravenously on Day 1 of a 21-day cycle, starting at 100 mg/m 2 /dose and AUC 5, respectively. Patients were enriched for molecular alterations in cell cycle and/or homologous recombination (HR). Results: Twenty patients (median age: 14.0 years; range: 3.4–23.5) were included; 18 received 69 treatment cycles. Dose-limiting toxicities were prolonged grade 4 neutropenia and grade 3/4 thrombocytopenia requiring transfusions, leading to two de-escalations to adavosertib 75 mg/m 2 /dose and carboplatin AUC 4; no recommended phase II dose was defined. Main treatment-related toxicities were hematologic and gastrointestinal. Adavosertib exposure in children was equivalent to that in adults; both doses achieved the cell kill target. Overall response rate was 11% (95% confidence interval, 0.0–25.6) with partial responses in 2 patients with neuroblastoma. One patient with medulloblastoma experienced unconfirmed partial response and 5 patients had stable disease beyond four cycles. Seven of these eight patients with clinical benefit had alterations in HR, replication stress, and/or RAS pathway genes with or without TP53 alterations, whereas TP53 pathway alterations alone (8/10) or no relevant alterations (2/10) were present in the 10 patients without benefit. Conclusions: Adavosertib–carboplatin combination exhibited significant hematologic toxicity. Activity signals and identified potential biomarkers suggest further studies with less hematotoxic DNA-damaging therapy in molecularly enriched pediatric cancers.

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (34)

Richard F Schlenk

Head of trials office

Ruprecht Karls Universität Heidelberg

GERMANY
View details

Frederick Klauschen

Professor, Chair

Ludwig-Maximilians-Universität München

GERMANY
View details

Bernhard Kuster

Technical University of Munich

GERMANY
View details

Nicolas ANDRE

Professor

Aix-Marseille Université Faculté de Medecine

FRANCE
View details

Ulrich Keller

Prof. Dr.

Charité - Universitätsmedizin Berlin

GERMANY
View details

Birgit Geoerger

Université Paris-Saclay

FRANCE
View details

Robert Bruce Russell

Professor

Ruprecht Karls Universität Heidelberg

GERMANY
View details

Xavier Paoletti

Professor

Institut Curie

FRANCE
View details

Samaneh Eickelschulte

Translational Research Scientist

University Hospital Heidelberg

GERMANY
View details

Ralf Mikut

Head of Research Area

Karlsruhe Institute of Technology

GERMANY
View details

Susanne Andrea Gatz

University of Birmingham

UNITED KINGDOM
View details

Robert Bruce Russell

Professor of Protein Evolution

Heidelberg University

GERMANY
View details

Holger Sültmann

Division Head / University Professor

German Cancer Research Center (DKFZ)

GERMANY
View details

Matthew The

Technical University of Munich

GERMANY
View details

Wolfgang Hartmann

MD, Consultant, Professor for Molecular Pathology

University Hospital Münster

GERMANY
View details

Cihan Erkut

Senior Scientist

Deutsches Krebsforschungszentrum

GERMANY
View details

Heiko Brennenstuhl

MD, MBA

Heidelberg University

GERMANY
View details

Peter Horak

Deputy Head of Department

UniversitätsKlinikum Heidelberg

GERMANY
View details

Arne Jahn

Technische Universität Dresden

GERMANY
View details

Simon Haas

Group leader

Deutsches Krebsforschungszentrum

GERMANY
View details

Michael Hundemer

Professor

University Hospital Heidelberg

GERMANY
View details

Christian H. Brandts

Professor & Director

Goethe University Frankfurt

GERMANY
View details

Matthias Schlesner

University of Augsburg

GERMANY
View details

Karsten Rippe

Head of Division

German Cancer Research Center (DKFZ)

GERMANY
View details

Oliver Stegle

Professor

Heidelberg University

GERMANY
View details

Claudia Ball

Head Preclinical Model Unit

German Cancer Research Center (DKFZ)

GERMANY
View details

Bernt Popp

Berlin Institute of Health at Charité - Universitätsmedizin Berlin

GERMANY
View details

Sebastian Bauer

Professor / Chair

Universität Duisburg-Essen

GERMANY
View details

Carsten Müller-Tidow

Medical Director

University Hospital Heidelberg

GERMANY
View details

Albrecht Stenzinger

-

GERMANY
View details

David Bonekamp

-

GERMANY
View details

Marc S. Raab

University Hospital Heidelberg

GERMANY
View details

Matthias Kroiss

Group leader

LMU University Hospital

GERMANY
View details

Judith B. Zaugg

University of Basel

SWITZERLAND
View details